The Moffitt Cancer Center requests renewal of its NCI Cancer Center Support Grant (CCSG) for years 14-18. Moffitt is a free-standing cancer center whose sole mission is """"""""to contribute to the prevention and cure of cancer."""""""" Research activities are focused around five programs: Molecular Oncology &Drug Discovery;Immunology;Experimental Therapeutics;Cancer Epidemiology, and Health Outcomes &Behavior. Fourteen shared resources provide broad support for these programs and our faculty. Over the last grant period, Moffitt has made significant progress. Extramural funding increased from $54.0 million to 82.6 million. Membership increased from 135 to 156 including the recruitment of 67 new faculty. Over 1,900 peer-reviewed publications were generated over the last 5 years by Moffitt members. Clinical intervention trial accrual averaged 1,176 subjects per year. Facilities projects included an $87 million investment that added 36 hospital beds, 40,000 sf of faculty office space, 2 linear accelerators and related support space that included an expanded Clinical Research Unit. A nexus freezer system, a fully automated and robotic biorepository system with a capacity of over 2.4 million tubes, was installed. Moffitt has invested in strategic initiatives to enhance our basic, population and clinical researc to strengthen the research programs and spur collaboration. These major initiatives include Total Cancer Care, Moffitt's bold long-term initiative to realize personalized cancer care by incorporating information on molecular characterization of the host and tumor into treatment decisions. Other initiatives include investments in lung cancer, melanoma, imaging research, integrated mathematical oncology, health disparities and diversity, and education and training. The Moffitt proposal includes funding requests for 5 programs, 14 shared resources, and 7 staff investigators. The increased budget will provide critical resources to support and enhance the Center's infrastructure, particularly the shared resources. The institution, with generous support from the State, has developed a solid research infrastructure that has successfully supported a rapid increase in peer-reviewed funding and publications in a short amount of time. We believe our success to date represents a healthy return on investment made by the NCI and the state of Florida.

Public Health Relevance

The Cancer Center Support Grant will provide Moffitt with resources for critical infrastructure to reduce the cancer burden throughout Florida and across the United States. Moffitt's singular focus on cancer and obligation to serve as the State of Florida's cancer center positions the center to make significant contributions to the prevention and cure of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA076292-16S3
Application #
8927154
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1998-02-18
Project End
2017-01-31
Budget Start
2014-03-03
Budget End
2015-01-31
Support Year
16
Fiscal Year
2014
Total Cost
$150,000
Indirect Cost
$60,979
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Davis, Stacy N; Govindaraju, Swapamthi; Jackson, Brittany et al. (2018) Recruitment Techniques and Strategies in a Community-Based Colorectal Cancer Screening Study of Men and Women of African Ancestry. Nurs Res 67:212-221
Martínez, Úrsula; Brandon, Thomas H; Sutton, Steven K et al. (2018) Associations between the smoking-relatedness of a cancer type, cessation attitudes and beliefs, and future abstinence among recent quitters. Psychooncology 27:2104-2110
Perales-Puchalt, Alfredo; Perez-Sanz, Jairo; Payne, Kyle K et al. (2018) Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. J Leukoc Biol 103:799-805
Nelson, Ashley M; Jim, Heather S L; Small, Brent J et al. (2018) Sleep disruption among cancer patients following autologous hematopoietic cell transplantation. Bone Marrow Transplant 53:307-314
Singh, Kshipra; Coburn, Lori A; Asim, Mohammad et al. (2018) Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses. Cancer Res 78:4303-4315
Kasting, Monica L; Giuliano, Anna R; Reich, Richard R et al. (2018) Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. Cancer Epidemiol Biomarkers Prev 27:503-513
Denson, Aaron; Burke, Nancy; Wapinsky, Georgine et al. (2018) Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. Am J Clin Oncol 41:133-139
Betts, Brian C; Bastian, David; Iamsawat, Supinya et al. (2018) Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci U S A 115:1582-1587
Pidala, Joseph; Beato, Francisca; Kim, Jongphil et al. (2018) In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica 103:531-539
Hampras, S S; Tommasino, M; Zhao, Y et al. (2018) Cross-sectional associations between cutaneous viral infections and regulatory T lymphocytes in circulation. Br J Dermatol :

Showing the most recent 10 out of 1254 publications